Journal · Decision guide

How do you check a GLP-1 provider ranking before you trust it?

Released: · Last reviewed: · By Dr. Parmis

Every GLP-1 comparison site puts someone first. These seven tests show whether the order comes from evidence you can repeat, and we apply them to our own scores first.

To check a GLP-1 provider ranking, test seven things: published weights and sub-checks, each program's inputs, dated first-party prices, a like-for-like price basis, FDA warning letters applied to every program, honest handling of programs the ranker could not read, and a clear relationship disclosure. A list that fails two or more is marketing, not measurement.

Takeaway: you do not need to trust a "best GLP-1 provider" list. You need to be able to redo it. Below, each test is applied to this site's own November 20, 2026 re-score of 15 programs, including the places where our earlier version failed.

Why GLP-1 rankings disagree so much

Search for the best online tirzepatide program and you will find lists that put a different company first on almost every page. Some of that is honest: one list weights price, another weights clinical support. Some of it is structural, because many lists are published by a company that sells the product or earns a commission from the programs it ranks.

NexLife is a useful example because it states its position openly. Its review methodology page, updated November 15, 2026, calls its guides "a conflict of interest: NexLife publishes these guides and sells compounded tirzepatide and semaglutide plans," and scores itself 9.7 out of 10 for both drugs. Its English best-of pages call NexLife "our top pick," while its Spanish comparison pages say NexLife "no se clasifica a sí misma" (does not rank itself). Disclosure like that is better than silence, but a self-score is not an independent score, whoever publishes it. The way to judge any ranking, including this one, is to see whether you could reproduce it.

Test 1: are the weights and sub-checks published?

Category weights alone are not enough. "Pricing transparency, 20 points" can hide any rule. Look for the sub-checks that turn a category into points: what earns full marks, what earns partial marks, and what earns nothing.

Our methodology splits the seven v4.1 categories into 17 sub-checks plus one cost formula. Clinical oversight, for example, gives 9 points for naming the prescribing medical group, 5 for a network label, 3 for naming only a physician executive and 2 for describing the arrangement without a name. Graded rules like that still involve judgment, but the judgment is written down.

Test 2: can you see each program's inputs?

A published score with no breakdown cannot be checked. Every review page on this site now shows each sub-check, the points earned and a note where the call needs one. This is the test our own earlier version failed: from November 10 to November 20, 2026 this site showed a fixed 94 out of 100 for NexLife before any other program had been scored, with no breakdown. When we scored all readable programs on the written rules, NexLife came out at 87.0. It lost 5 points for an open FDA warning letter, 3 because its own price figures disagree, 3 because its pages disagree on whether multi-month plans are billed monthly or upfront, and 2 because they disagree on how many states it serves. It still ranks first. The change is logged on our corrections page.

Test 3: are the prices first-party and dated?

GLP-1 prices move between reads. In the November 20 re-read, Found had cut its cash price for compounded tirzepatide on a 12-month term from $239 to $199 per 28-day cycle since October 15, and Henry Meds no longer printed an injectable tirzepatide price at all. A ranking that does not show where each price came from, and on what date, may be scoring last season's market. Look for a seller domain and a read date beside every figure, as on our price page.

Test 4: is the price comparison like for like?

A month-to-month price, a 12-month prepaid price and a starting-dose price are three different offers. A fair cost score converts them to the same basis. Ours uses the cheapest plan a new patient could buy for a year, including any required membership: 12 monthly shipments, or 13 four-week cycles for programs that bill that way.

Two examples show why the basis matters. NexLife's 12-month tirzepatide plan is 12 × $115 = $1,380 at its prices as of November 6, 2026. Found's 12-month cash term is 13 × $199 = $2,587, because Found bills every 28 days. Mochi Health prints $90 for its starting tirzepatide dose plus a $49 monthly membership on a 12-month plan (read November 20, 2026), or $1,668 a year, but higher doses cost more and the ladder is not printed. We count that figure as a minimum at half weight rather than as a real annual cost. A list that ranks Mochi on its $90 sticker is comparing a starting dose with other programs' every-dose prices.

Test 5: are FDA warning letters applied to everyone?

FDA's warning-letter index, read November 20, 2026, lists open letters to six of the 20 programs we review: Hims & Hers, MEDVi, IVIM Health, Zappy Health, Eden and NexLife. A ranking that mentions one company's letter and not the others, or that takes points from competitors but not from its own pick, fails this test.

Our rule removes 5 points for any open letter. It is worth seeing what that one rule does to the order:

How the November 20, 2026 order changes under three alternative rules (GLP Ranked v4.1 scores; totals out of 100, or 80 without the annual-cost category)
ScenarioFirstSecondThirdPrograms that change place
Published rulesNexLife 87.0Eden 85.2Enhance.MD 81.6None (baseline)
No points for or against FDA warning lettersNexLife 92.0Eden 90.2Enhance.MD 81.65: Zappy Health up to 5th, Mochi Health down to 6th, IVIM Health up from 10th to 8th, Noom Med and Form Health down one place
No annual-cost category (80 points)Enhance.MD 74.0Found 69.0NexLife 67.010: Enhance.MD and Found move to first and second, NexLife and Eden drop to third and fourth; IVIM Health, Oak Longevity and Shed tie at 47.0
Eden's Chief Medical Innovation Officer counted as a clinical lead (CO3)Eden 88.2NexLife 87.0Enhance.MD 81.62: Eden and NexLife swap

The first place is not robust, and a fair ranking should say so. Drop the annual-cost category and two programs that print one price at every dose but charge more, Enhance.MD and Found, move ahead. Count Eden's physician executive as a clinical lead and Eden leads by 1.2 points. Under the written rules, NexLife gains 9 points on Eden by naming its medical group and a medical director, plus 0.8 because its 12-month price is below Eden's month-to-month price, the only plan Eden prints; Eden wins back 8 because its own pages agree with each other on prices, billing and where it operates. A ranking that shows this arithmetic lets you decide whether its weights match your priorities.

Computed scores of 15 GLP-1 telehealth programs, split into price points and disclosure points Stacked horizontal bars out of 100. NexLife 34 plus 53 equals 87. Eden 39.2 plus 46 equals 85.2. Enhance.MD 27.6 plus 54 equals 81.6. Found 31.8 plus 49 equals 80.8. Mochi Health 23.7 plus 49 equals 72.7. Zappy Health 29.1 plus 39 equals 68.1. Henry Meds 29.6 plus 37 equals 66.6. Noom Med 19.4 plus 37 equals 56.4. Form Health 0 plus 55 equals 55. IVIM Health 16.8 plus 37 equals 53.8. WeightWatchers Clinic 5 plus 47 equals 52. Shed 9.8 plus 42 equals 51.8. Oak Longevity 5 plus 42 equals 47. PlushCare 0 plus 46 equals 46. Calibrate 5 plus 37 equals 42. NexLife87.0 Eden85.2 Enhance.MD81.6 Found80.8 Mochi Health72.7 Zappy Health68.1 Henry Meds66.6 Noom Med56.4 Form Health55.0 IVIM Health53.8 WeightWatchers Clinic52.0 Shed51.8 Oak Longevity47.0 PlushCare46.0 Calibrate42.0 050100 Price points (pricing transparency + annual cost, of 40) Disclosure points (of 60)
Chart: each program's computed v4.1 total, split into price points (pricing transparency and total annual cost, 40 available) and disclosure points (clinical, pharmacy, support, regulatory and accessibility, 60 available). Source: GLP Ranked scores computed November 20, 2026; the per-program inputs are on each review page and the totals are in the methodology's score table.

A worked check in five minutes

Try the tests on any list you are reading. Pick its first-place program and its fifth. Find the breakdown for each, then confirm one price on each program's own page and note the date. Look both programs up in FDA's warning-letter index. If the list's arithmetic, prices and letters all match what you find, the order is at least reproducible. If you cannot find a breakdown at all, you have learned the most important thing about that list in under a minute.

Test 6: what happens to programs the ranker could not read?

Some programs block automated reads or show prices only after a quiz. A ranking can give those programs zeros, quietly drop them, or say plainly that they were not scored. The first punishes a program for the ranker's limits; the second hides the gap. We list five programs as not scored, each with its reason: Ro Body and bmiMD returned HTTP 403 in the November 20 re-read, Hims & Hers was unreachable that day, and TrimRx and MEDVi showed prices only in a browser. Five scored programs print no drug-specific medication price and get no annual-cost points. That is a different situation: we could read their pages, and the pages did not say.

Test 7: does the publisher disclose its relationship?

The FTC's Endorsement Guides (16 CFR Part 255) expect a material connection between an endorser and a seller to be disclosed clearly, and Google's guidance on writing high-quality reviews asks reviewers to show evidence and explain how they tested. Look for a disclosure you can find without hunting, and check that the scoring rules stay the same for the publisher's own pick. This site is affiliate-supported; the disclosure is in every page footer and on our disclosure page.

What this means for you

  • Before you trust a list, find its sub-checks and one program's full breakdown. If you cannot, treat the order as an opinion.
  • Re-do the price comparison on one basis yourself: the same drug, the same plan length, every required fee.
  • Check FDA's warning-letter index for every program on your shortlist, not only the ones a list mentions.
  • Read a "not scored" or "unverified" label as useful information, not as a mark against the program.
  • Pick the program whose strengths match your priority. If you care most about who fills the vial, start with our pharmacy records article.

Method and limits

The scenarios above recompute our published totals with one rule removed at a time; they are not alternative rankings we endorse. Prices come from the November 20, 2026 portfolio re-read of each program's own pages, and disclosure checks from reads on November 10 and 21. Sub-check judgments, such as whether a statement counts as naming a pharmacy, are noted on each review page so a reader can disagree with a specific call.

Frequently asked questions

Can a GLP-1 provider rank itself fairly?

A provider can publish its own comparison and disclose that it sells the product, as NexLife does on its methodology page, but its self-score is not independent. Judge such a list by the same tests as any other: published sub-checks, each program's inputs, dated first-party prices and the same rules applied to the publisher's own program.

Why does GLP Ranked score NexLife 87.0 instead of 94?

The 94 was a fixed figure shown from November 10 to November 20, 2026 before other programs were scored. On November 20 every readable program was scored on 17 written sub-checks. NexLife lost 5 points for an open FDA warning letter, 3 for conflicting price figures, 3 for conflicting billing statements and 2 for conflicting state statements, giving 87.0, still first of 15 by 1.8 points.

Should an FDA warning letter remove a program from a ranking?

Not necessarily. A warning letter is a formal notice of violations, not a ban, and FDA lists open letters to several large telehealth programs. What matters is consistency: a ranking should apply the same rule to every program with a letter, state each letter by number and date, and say whether FDA has posted a close-out.

What is a like-for-like price comparison for GLP-1 programs?

It compares the same drug on the same plan length with every required fee included. A fair annual figure uses the cheapest plan a new patient can buy for a year: 12 monthly shipments, or 13 four-week cycles for programs that bill every 28 days. Starting-dose prices should be labelled as minimums, not treated as every-dose prices.

Why are some programs listed as not scored?

Because their own pages could not be read on the re-read date: some returned HTTP 403 errors and others showed prices only inside a browser. Scoring them zero would penalize them for the ranker's limits, and dropping them silently would hide the gap, so each one is listed with its reason and will be scored once its pages can be read.

How often should a GLP-1 ranking be recomputed?

Whenever material evidence changes, such as a price change, a new FDA letter or a program that starts naming its pharmacy, and at least on each scheduled re-read. A ranking should show the date of its last computation and the read date of every price, so you can see how old each input is.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Sources

  1. NexLife: GLP-1 review methodology (self-score and conflict-of-interest statement) — updated November 15, 2026; read 2026-11-21; provider-reported
  2. NexLife: Mejores proveedores de semaglutida (Spanish page: 'no se clasifica a sí misma') — read 2026-11-20 (portfolio research); provider-reported
  3. NexLife: Best tirzepatide providers ('our top pick') — updated November 15, 2026; read 2026-11-21; provider-reported
  4. FTC: Guides Concerning the Use of Endorsements and Testimonials in Advertising, 16 CFR Part 255 (eCFR) — read 2026-11-21; regulation
  5. Google Search Central: Write high-quality reviews — read 2026-11-21; documentation
  6. FDA: Warning letters index — read 2026-11-20; regulator
  7. FDA warning letter 730096 to Nexlife Inc. — dated June 8, 2026; read 2026-11-20; regulator
  8. FDA warning letter 728279 to Eden Health International Inc. — dated June 8, 2026; read 2026-11-20; regulator
  9. Found: compounded tirzepatide store page (cash-pay terms) — read 2026-11-20; provider-reported
  10. Mochi Health: FAQs (membership and starting-dose prices) — read 2026-11-20; provider-reported
  11. NexLife: Compounded tirzepatide plans — prices unchanged on re-read 2026-11-20; provider-reported

Cite this page

GLP Ranked. "How do you check a GLP-1 provider ranking before you trust it?." https://glpranked.com/journal/how-to-check-a-glp1-provider-ranking/

GLP Ranked. "How do you check a GLP-1 provider ranking before you trust it?." https://glpranked.com/journal/how-to-check-a-glp1-provider-ranking/